Abstract
Alzheimer's disease (AD) pathology has been described in Parkinson's disease (PD) patients with leucine-rich repeat kinase-2 (LRRK2) mutations. A common LRRK2 Gly2385Arg variant has been widely shown to be associated with a twofold increased risk of PD in various Asian populations. In a case control study, the frequency of the heterozygous Gly2385Arg genotype was demonstrated in 4.3% of AD compared to 4.5% in controls (odds ratio=0.94, 95% CI 0.37-2.42, p=1.0). The Gly2385Arg variant does not appear to modulate the risk of AD in our population.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Alzheimer Disease / diagnosis
-
Alzheimer Disease / genetics*
-
Amino Acid Substitution / genetics*
-
Arginine / genetics*
-
Case-Control Studies
-
Female
-
Genetic Carrier Screening
-
Genetic Variation / genetics
-
Glycine / genetics*
-
Humans
-
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
-
Male
-
Middle Aged
-
Mutation / genetics
-
Protein Serine-Threonine Kinases / genetics*
-
Risk Factors
Substances
-
Arginine
-
LRRK2 protein, human
-
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
-
Protein Serine-Threonine Kinases
-
Glycine